Tolerogenic vaccines for multiple sclerosis
Author
Mannie, Mark D.; Curtis II, Alan Dale
Abstract
Tolerogenic vaccines represent a new class of vaccine designed to re-establish immunological tolerance, restore immune homeostasis, and thereby reverse autoimmune disease. Tolerogenic vaccines induce long-term, antigen-specific, inhibitory memory that blocks pathogenic T cell responses via loss of effector T cells and gain of regulatory T cell function. Substantial advances have been realized in the generation of tolerogenic vaccines that inhibit experimental autoimmune encephalomyelitis in a preclinical setting, and these vaccines may be a prequel of the tolerogenic vaccines that may have therapeutic benefit in Multiple Sclerosis. The purpose here is to provide a snapshot of the current concepts and future prospects of tolerogenic vaccination for Multiple Sclerosis, along with the central challenges to clinical application.
Date
2013-01-28
Citation:
APA:
Mannie, Mark D., & Curtis II, Alan Dale. (January 2013).
Tolerogenic vaccines for multiple sclerosis.
,
(),
-
. Retrieved from
http://hdl.handle.net/10342/7818
MLA:
Mannie, Mark D., and Curtis II, Alan Dale.
"Tolerogenic vaccines for multiple sclerosis". .
. (),
January 2013.
September 30, 2023.
http://hdl.handle.net/10342/7818.
Chicago:
Mannie, Mark D. and Curtis II, Alan Dale,
"Tolerogenic vaccines for multiple sclerosis," , no.
(January 2013),
http://hdl.handle.net/10342/7818 (accessed
September 30, 2023).
AMA:
Mannie, Mark D., Curtis II, Alan Dale.
Tolerogenic vaccines for multiple sclerosis. .
January 2013;
():
.
http://hdl.handle.net/10342/7818. Accessed
September 30, 2023.
Collections